⌕
Avalo Therapeutics · AVTX · Nasdaq
Tenet 55 · Mixed
Compare
$6.76+0.15%At closeTenet 55 · Mixed
$6.76+0.01 (+0.15%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD

Avalo Therapeutics (AVTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 100% below its peak, net margin −132642.4%.
The four lines that matter · FY21–FY25
Revenue ($K)▼86.6%
59.0
FY21→FY25CAGR −67.7%/yr
Net income ($K)▼122.8%
−78,259.0
FY21→FY25CAGR —
Free cash flow ($K)—
—
no FY25 valueCAGR —
Diluted EPS—
−5.84
no value for 4 of 5 yearsCAGR —
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)59.0Revenue0.0COGS−50084.0R&D−22900.0SG&A−72925.0Op income−5334.0Tax & other−78259.0Net income

-132642¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
19014395480%FY21FY25

Net margin -132642.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.2435, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
59.059.0441.01,924.018,051.05,398.0▼86.6%−67.7%
Cost of revenue
—0.0−366.01,284.03,434.01,491.0——
Gross profit
59.0—807.0640.014,617.03,907.0——
Research & development
65,777.050,084.052,078.013,784.031,308.059,835.0▼3.8%−4.3%
Selling, general & admin
29,839.022,900.017,241.010,300.020,711.024,658.0▲32.8%−1.8%
Total operating expenses
95,616.072,984.069,319.027,991.052,057.086,041.0▲5.3%−4.0%
Operating incomefeeds ROC rank
−95,557.0−72,925.0−68,512.0−27,351.0−37,440.0−82,134.0▼6.4%—
Other income, net
7,071.0−5,169.033,497.0−4,179.0−4,190.0−2,411.0——
Pretax income
−88,486.0−78,094.0−35,015.0−31,530.0−41,630.0−84,545.0▼123.0%—
Income tax
167.0165.0114.014.028.0−196.0▲44.7%+80.6% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−88,653.0−78,259.0−35,129.0−31,544.0−41,658.0−84,376.0▼122.8%—
Per share
Diluted EPSbuyback-sensitive
—−5.84——————
Diluted shares (mn)
—13.40——————
Margins
Gross margin80th pct in Healthcare
100.0%—183.0%33.3%81.0%72.4%——
Operating margin
−161961.0%−123601.7%−15535.6%−1421.6%−207.4%−1521.6%▼108066.1pp−122080.1pp
Net margin0th pct in Healthcare
−150259.3%−132642.4%−7965.8%−1639.5%−230.8%−1563.1%▼124676.6pp−131079.3pp
† TTM = trailing four quarters through 2026-09-30.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Avalo Therapeutics' revenue last fiscal year?

Avalo Therapeutics reported revenue of $59.0K in fiscal 2025, down 86.6% from fiscal 2024.

What was Avalo Therapeutics' net income?

Avalo Therapeutics reported net income of −$78,259.0K in fiscal 2025, a net margin of −132642.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.